Six months versus two years of oral anticoagulation after a first episode of unprovoked deep-vein thrombosis. The PADIS-DVT randomized clinical trial

Figures

• 

  Figure 1.. Patients’ flow through the study.

• 

  Figure 2.. Kaplan-Meier estimates of the probability of the composite outcome of recurrent venous thromboembolism and major bleeding during the entire study period, according to study group. The unadjusted hazard ratios (95% confidence interval) warfarin/placebo were 0.03 (0.01 to 0.51) during the treatment period and 0.72 (0.35 to 1.46) during the entire study period.

• 

  Figure 3.. Meta-analysis of the PADIS-PE and PADIS-DVT studies. Pooled hazard ratios were calculated for the composite of recurrent venous thromboembolism and major bleeding and for the recurrent venous thromboembolism component. The pooled hazard ratio for the component of major bleeding is not reported as there was no major bleeding in the placebo group of the PADIS-DVT trial. HR: hazard ratio; 95% CI: 95% confidence interval; PE: pulmonary embolism; DVT: deep-vein thrombosis.